Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

• Nicola Gianotti ,

  * E-mail: nicola.gianotti@hsr.it

  Affiliation San Raffaele Hospital, Milano, Italy

  http://orcid.org/0000-0002-7182-5080

  ⨯
• Alessandro Cozzi-Lepri,

  Affiliation University College London, London, United Kingdom

  ⨯
• Andrea Antinori,

  Affiliation National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy

  ⨯
• Antonella Castagna,

  Affiliations San Raffaele Hospital, Milano, Italy, Università Vita-Salute San Raffaele, Milano, Italy

  ⨯
• Andrea De Luca,

  Affiliation University of Siena, Siena, Italy

  ⨯
• Benedetto Maurizio Celesia,

  Affiliation University of Catania, Catania, Italy

  ⨯
• Massimo Galli,

  Affiliation Luigi Sacco Hospital, Milano, Italy

  ⨯
• Cristina Mussini,

  Affiliation University of Modena, Modena, Italy

  ⨯
• Carmela Pinnetti,

  Affiliation National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy

  ⨯
• Vincenzo Spagnuolo,

  Affiliation San Raffaele Hospital, Milano, Italy

  ⨯
• Antonella d’Arminio Monforte,

  Affiliation San Paolo Hospital, Milano, Italy

  ⨯
• Francesca Ceccherini-Silberstein,

  Affiliation University of Rome Tor Vergata, Roma, Italy

  ⨯
• Massimo Andreoni,

  Affiliation University of Rome Tor Vergata, Roma, Italy

  ⨯
• On behalf of Icona Foundation Study and mono-PI/r database Study Cohorts

  ¶Membership of the Icona Foundation Study and mono-PI/r database Study Cohorts is provided in the Acknowledgments.

  ⨯